Last $3.75 USD
Change Today -0.03 / -0.79%
Volume 269.9K
CYTK On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Key Developments

Cytokinetics, Incorporated Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cytokinetics, Incorporated reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Revenues for the second quarter of 2014 were $7.8 million, compared to $1.0 million during the same period in 2013. The net loss for the second quarter was $8.4 million, or $0.23 per basic and diluted share. This is compared to a net loss for the same period in 2013, of $15.0 million, or $0.58 per basic and diluted share. Operating loss was $8,407,000 against $15,068,000 a year ago. Revenues for the six months ended June 30, 2014 were $15.8 million, compared to $1.8 million for the same period in 2013. The net loss for the six months ended June 30, 2014, was $17.1 million, or $0.49 per basic and diluted share, compared to a net of $27.7 million, or $1.11 per basic and diluted share, for the same period in 2013. Operating loss was $17,177,000 against $27,715,000 a year ago.

Cytokinetics, Incorporated to Report Q2, 2014 Results on Jul 30, 2014

Cytokinetics, Incorporated announced that they will report Q2, 2014 results at 4:00 PM, US Eastern Standard Time on Jul 30, 2014

Cytokinetics, Incorporated, Q2 2014 Earnings Call, Jul 30, 2014

Cytokinetics, Incorporated, Q2 2014 Earnings Call, Jul 30, 2014

Cytokinetics, Incorporated Announces Additional Results from BENEFIT-ALS

Cytokinetics, Incorporated announced that additional results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) were presented during a poster presentation at the 13th International Congress on Neuromus cular Diseases in Nice, France. The results from pre-specified subgroup analyses of BENEFIT-ALS were presented by Andrew A. Wolff, M.D., F.A.C.C., Senior Vice President, Clinical Research and Development, and Chief Medical Officer of Cytokinetics. These results indicate that the reduced decline in Slow Vital Capacity on tirasemtiv versus placebo in BENEFIT-ALS were observed consistently across all subgroups of patients with amyotrophic lateral sclerosis (ALS). The effects of tirasemtiv versus placebo on the changes from baseline to the average score after 8 and 12 weeks of treatment for the primary and secondary endpoints were evaluated in pre-specified analyses of subgroups based on age, sex, geography, riluzole use, onset of disease, weight, body-mass index (BMI) and baseline respiratory function. Based on these results, the authors concluded that tirasemtiv reduced the decline in SVC versus placebo by a similar magnitude regardless of age (=65 versus <65), sex, geographic region (Europe versus North America), riluzole use, site of ALS onset (bulbar versus limb), baseline pulmonary function, baseline weight, and baseline BMI. The reduced decline in SVC versus placebo was statistically significant within each subgroup examined except patients enrolled in Europe, those with bulbar onset, and those with a percent predicted SVC less the median at baseline. The authors concluded that tirasemtiv may have both immediate and longer term pharmacologic effects, especially on SVC, and that the potentially beneficial effects of tirasemtiv on measures of respiratory function and other assessments of skeletal muscle performance observed in BENEFIT-ALS merit further investigation. In addition, analyses presented indicated that tirasemtiv had no effect on Maximum Voluntary Ventilation (MVV) in any subgroup examined; however, a trend toward an increase in MVV on tirasemtiv versus placebo in patients with bulbar onset approached statistical significance. Overall, Sniff Nasal Inspiratory Pressure (SNIP) was reduced on tirasemtiv versus placebo and the magnitude of this effect was similar across all subgroups except in patients older than 65 years, in whom a marginal increase was observed. Conversely, the only subgroup in which the reduction of SNIP on tirasemtiv versus placebo was statistically significant was in patients less than 65 years old. In these subgroup analyses, tirasemtiv had no effect on the changes in muscle strength and in handgrip fatigue from baseline to the average after 8 and 12 weeks, neither overall nor within any of the subgroups.

Cytokinetics, Incorporated Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 10:30 AM

Cytokinetics, Incorporated Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 10:30 AM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Robert I. Blum, Chief Executive Officer, President, Director and Chief Executive of the Biopharmaceutical Concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $3.75 USD -0.03

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.23 USD -0.01
Array BioPharma Inc $3.76 USD +0.01
CTI BioPharma Corp $2.51 USD +0.01
Curis Inc $1.57 USD -0.01
Exelixis Inc $1.62 USD -0.12
View Industry Companies
 

Industry Analysis

CYTK

Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.